Competitive Landscape · Objective Analysis
AenoFeed SC-1 vs. Bovaer (3-NOP)
An Honest Comparison
Both products target enteric methane reduction in ruminants via completely different mechanisms and evidence bases. This page compares them on verifiable dimensions only — no cost-per-head comparisons are asserted.
This analysis was prepared by Aenon. Independent verification recommended.
Editorial Note
What This Page Is (and Is Not)
This analysis is prepared by Aenon — a party with an obvious commercial interest. Readers should apply appropriate scepticism and verify claims independently. Where possible, we have cited the basis for each statement and labelled the evidence tier.
What this page does NOT contain:
- Cost-per-head or cost-per-dose comparisons (AenoFeed SC-1 commercial pricing not established)
- Claims that AenoFeed SC-1 outperforms Bovaer in efficacy (insufficient evidence)
- Statements about Bovaer's safety, regulatory issues, or business practices
- Market share projections or competitive displacement claims
Bovaer is a registered trademark of DSM-Firmenich. Aenon has no commercial relationship with DSM-Firmenich.
Comparison Matrix
Side-by-Side Overview
| Dimension | AenoFeed SC-1 (Aenon) | Bovaer / 3-NOP (DSM-Firmenich) |
|---|---|---|
| Active ingredient | SSF-fermented seaweed blend (E. denticulatum + K. alvarezii, proprietary ratio) | 3-nitrooxypropanol (3-NOP) — synthetic small molecule |
| Origin | Natural: marine macroalgae, fermentation-modified | Synthetic: chemical synthesis |
| Mechanism of action | Dual: (1) archaea membrane disruption by sulphated polysaccharides; (2) H₂→propionate redirection by fermentation metabolites In-Vitro Hypothesis | Direct inhibition of methyl-CoM reductase (MCR) enzyme in methanogenic archaea — well-characterised mechanism with multiple peer-reviewed studies |
| Bromoform content | None — neither Spinosum nor Cottonii contains bromoform ✅ GREEN | None — 3-NOP does not contain bromoform |
| Reported in-vitro efficacy | ~50% CH₄ inhibition (internal, preliminary, gas production assay, n=3) Preliminary | Extensive peer-reviewed in-vitro data — up to 90%+ inhibition in some assays (well-established) |
| In-vivo efficacy (published) | No published in-vivo data (trial planned Q4 2026) ⚠ Pending | Multiple peer-reviewed publications — 20–30% methane reduction in cattle (in-vivo, respiration chamber and SF6 tracer methodology) |
| Commercial availability | Development stage — not commercially available ⚠ Pre-commercial | Commercially available in multiple markets (EU, USA, Australia, etc.) |
| Regulatory approval | Korea Feed Act registration not yet initiated — awaiting in-vivo data | Approved in EU, USA (FDA GRAS), Australia, NZ, Brazil, and others |
| Patent / IP | Proprietary SSF process and formulation — core technology protected as trade secret ✅ Proprietary | Extensive patent portfolio (DSM-Firmenich) |
| Feed integration | Dry powder — premix or direct TMR addition at a proprietary reference level (developmental) | Liquid or encapsulated pellet — specific premix integration required; cold chain sensitivity |
| Natural-origin label | Yes — seaweed-based, fermentation-modified | No — synthetic origin |
| Cost (commercial) | Not established — AenoFeed SC-1 pricing not public | Pricing available from DSM-Firmenich distributors; varies by market |
| Evidence maturity | Early-stage: in-vitro only (2025) ⚠ Early | Mature: 10+ years of research, multiple published RCTs, commercialised |
Bovaer data sourced from publicly available peer-reviewed literature and DSM-Firmenich product information. AenoFeed SC-1 data is from Aenon internal R&D — independently unverified as of August 2026.
Dimension Analysis
Key Differentiating Dimensions
Mechanism of Action
AenoFeed SC-1
Proposed dual mechanism — sulphated polysaccharide-mediated archaea disruption + H₂ redirection toward propionate.
Neither mechanism is definitively established — both are hypotheses supported by in-vitro observations.
In-Vitro Hypothesis
Bovaer (3-NOP)
Precisely characterised: 3-NOP is a structural analog of coenzyme B, competitively inhibiting methyl-CoM reductase — the enzyme catalysing the final step of methanogenesis.
This mechanism is documented in multiple peer-reviewed publications.
The proposed AenoFeed SC-1 mechanisms are compatible with published literature on sulphated polysaccharide bioactivity and lactic acid bacteria metabolites — but have not been specifically confirmed for this substrate-strain combination in ruminant conditions.
Origin & Feed Labelling
AenoFeed SC-1
Natural-origin: derived from marine macroalgae via solid-state fermentation.
Potential for "natural feed ingredient" or "fermented seaweed" labelling in markets where such categories apply.
Regulatory determination depends on jurisdiction. Neither bromoform content nor synthetic processing steps are involved.
Bovaer (3-NOP)
Synthetic origin. Classified as a "feed additive" under EU regulation, not a "natural ingredient".
Some consumer-facing "clean label" feed concepts may require natural-origin documentation — Bovaer does not qualify under most natural-ingredient definitions.
Evidence Maturity
AenoFeed SC-1
In-vitro only (2025). No published peer-reviewed papers specific to this product. In-vivo trial planned Q4 2026.
AenoFeed SC-1 is at the pre-clinical stage.
The ~50% in-vitro result is promising but cannot be compared to Bovaer's mature in-vivo dataset.
⚠ Early Stage
Bovaer (3-NOP)
Mature evidence base: 10+ years of research, multiple randomised controlled trials (RCTs) in dairy cows, beef cattle, and sheep.
Published in peer-reviewed journals including Nature Food, Journal of Dairy Science, and others.
20–30% methane reduction consistently reported across multiple studies.
Feed Integration
AenoFeed SC-1
Dry powder format — compatible with standard compound feed premix blending and TMR (total mixed ration) mixing.
No cold chain requirement.
Inclusion at 5 g/kg DM (developmental reference — not final commercial spec).
Bovaer (3-NOP)
Available in liquid concentrate form and via premix integration.
Reported sensitivity to heat and oxidation in some formulations.
Requires specific premix infrastructure.
Established commercial integration protocols available from DSM-Firmenich.
Market Perspective
The Enteric Methane Market
Is Not Zero-Sum
Livestock methane reduction is a significant, under-served market. Multiple product approaches are needed to serve diverse livestock production systems, regulatory jurisdictions, and consumer preferences. Natural-origin alternatives to synthetic additives serve a distinct market segment.
🌊
Natural-Origin Market
Retailers, brands, and consumers increasingly demand natural-origin feed ingredients.
AenoFeed SC-1 targets this segment specifically.
🌏
Asia-Pacific Market
Korea and Southeast Asia are emerging methane regulation markets.
Aenon is positioned to serve this region with a locally-developed, regionally-relevant product.
💡
Mechanism Diversity
Multiple inhibition mechanisms reduce the risk of methane rebound through microbial adaptation —
a concern noted in some 3-NOP literature.